BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 34238657)

  • 1. Real-world burden of illness and unmet need in locally advanced or metastatic urothelial carcinoma following discontinuation of PD-1/L1 inhibitor therapy: A Medicare claims database analysis.
    Morgans AK; Hepp Z; Shah SN; Shah A; Petrilla A; Small M; Sonpavde G
    Urol Oncol; 2021 Oct; 39(10):733.e1-733.e10. PubMed ID: 34238657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidemiology and treatment patterns for locally advanced or metastatic urothelial carcinoma: a systematic literature review and gap analysis.
    Hepp Z; Shah SN; Smoyer K; Vadagam P
    J Manag Care Spec Pharm; 2021 Feb; 27(2):240-255. PubMed ID: 33355035
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical and Patient-Reported Outcomes of Advanced Urothelial Carcinoma Following Discontinuation of PD-1/L1 Inhibitor Therapy.
    Morgans AK; Grewal S; Hepp Z; Fuldeore R; Odak S; Macahilig C; Shillington AC; Sonpavde G
    Clin Genitourin Cancer; 2022 Dec; 20(6):543-552. PubMed ID: 36088235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world treatment patterns and clinical outcomes with first-line therapy in patients with locally advanced/metastatic urothelial carcinoma by cisplatin-eligibility.
    Morgans AK; Galsky MD; Wright P; Hepp Z; Chang N; Willmon CL; Sesterhenn S; Liu Y; Sonpavde GP
    Urol Oncol; 2023 Aug; 41(8):357.e11-357.e21. PubMed ID: 37208230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First-line immune-checkpoint inhibitor combination therapy for chemotherapy-eligible patients with metastatic urothelial carcinoma: A systematic review and meta-analysis.
    Mori K; Pradere B; Moschini M; Mostafaei H; Laukhtina E; Schuettfort VM; Sari Motlagh R; Soria F; Teoh JYC; Egawa S; Powles T; Shariat SF;
    Eur J Cancer; 2021 Jul; 151():35-48. PubMed ID: 33962359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world outcomes in locally advanced or metastatic urothelial carcinoma following platinum and PD-1/L1 inhibitor therapy.
    Hepp Z; Shah SN; Liang SY; Tan K; Balakrishna S
    Future Oncol; 2021 Nov; 17(32):4343-4353. PubMed ID: 34350778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and Economic Outcomes in Patients With Metastatic Urothelial Carcinoma Receiving First-Line Systemic Treatment (the IMPACT UC I Study).
    Bilen MA; Robinson SB; Schroeder A; Peng J; Kim R; Liu FX; Bhanegaonkar A
    Oncologist; 2023 Sep; 28(9):790-798. PubMed ID: 37432283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overall survival, costs, and healthcare resource use by line of therapy in Medicare patients with newly diagnosed metastatic urothelial carcinoma.
    Aly A; Johnson C; Yang S; Botteman MF; Rao S; Hussain A
    J Med Econ; 2019 Jul; 22(7):662-670. PubMed ID: 30836812
    [No Abstract]   [Full Text] [Related]  

  • 9. Health Care Resource Utilization and Costs Among Medicare Beneficiaries Newly Diagnosed With Peripheral T-cell Lymphoma: A Retrospective Claims Analysis.
    Shah A; Petrilla A; Rebeira M; Feliciano J; Lisano J; LeBlanc TW
    Clin Lymphoma Myeloma Leuk; 2021 Jan; 21(1):e1-e9. PubMed ID: 33184000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Focus on Biochemical and Clinical Predictors of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma: Where Do We Stand?
    Roviello G; Catalano M; Nobili S; Santi R; Mini E; Nesi G
    Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33114616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative Effectiveness of Immune Checkpoint Inhibitors in Patients with Platinum Refractory Advanced Urothelial Carcinoma.
    Swami U; Haaland B; Kessel A; Nussenzveig R; Maughan BL; Esther J; Sirohi D; Pal SK; Grivas P; Agarwal N
    J Urol; 2021 Mar; 205(3):709-717. PubMed ID: 33080152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health-related Quality of Life of Patients with Locally Advanced or Metastatic Urothelial Cancer Treated with Enfortumab Vedotin after Platinum and PD-1/PD-L1 Inhibitor Therapy: Results from Cohort 1 of the Phase 2 EV-201 Clinical Trial.
    McGregor B; O'Donnell PH; Balar A; Petrylak D; Rosenberg J; Yu EY; Quinn DI; Heath EI; Campbell M; Hepp Z; McKay C; Steinberg J; Regnault A; Mazerolle F; Galsky MD
    Eur Urol; 2022 May; 81(5):515-522. PubMed ID: 35168844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Research progress on PD-1 and PD-L1 inhibitors in the treatment of metastatic urothelial carcinoma.
    Tang Q; Li S; Huang G; Liu H
    Int Immunopharmacol; 2023 Jun; 119():110158. PubMed ID: 37062259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment with opioids in patients with locally advanced or metastatic urothelial carcinoma and matched non-cancer controls.
    Galsky MD; Grewal S; Liu Y; Fuldeore R; Sesterhenn S; Chang N; Hepp Z
    Urol Oncol; 2022 Sep; 40(9):411.e9-411.e18. PubMed ID: 35927156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Impact of Progression on Healthcare Resource Utilization and Costs Among Patients with High-Grade Non-Muscle Invasive Bladder Cancer After Bacillus Calmette-GuĂ©rin Therapy: A Retrospective SEER-Medicare Analysis.
    Yang M; Georgieva MV; Bocharova I; Vembusubramanian M; Qian K; Guo A; Kamat AM
    Adv Ther; 2021 Mar; 38(3):1584-1600. PubMed ID: 33543424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive Role of Computed Tomography Texture Analysis in Patients with Metastatic Urothelial Cancer Treated with Programmed Death-1 and Programmed Death-ligand 1 Inhibitors.
    Alessandrino F; Gujrathi R; Nassar AH; Alzaghal A; Ravi A; McGregor B; Sonpavde G; Shinagare AB
    Eur Urol Oncol; 2020 Oct; 3(5):680-686. PubMed ID: 31412003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequencing of PD-1/L1 Inhibitors and Carboplatin Based Chemotherapy for Cisplatin Ineligible Metastatic Urothelial Carcinoma.
    Wei XX; Werner L; Teo MY; Rosenberg JE; Koshkin VS; Grivas P; Szabados B; Morrison L; Powles T; Carril-Ajuria L; Castellano D; Velho PI; Hahn NM; McKay RR; Raggi D; Necchi A; Kanesvaran R; Alerasool P; Gaines J; Galsky M; Bellmunt J; Sonpavde G
    J Urol; 2021 Feb; 205(2):414-419. PubMed ID: 32935617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyperprogressive Disease in Patients With Urothelial Carcinoma or Renal Cell Carcinoma Treated With PD-1/PD-L1 Inhibitors.
    Hwang I; Park I; Yoon SK; Lee JL
    Clin Genitourin Cancer; 2020 Apr; 18(2):e122-e133. PubMed ID: 31837940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world effectiveness and safety of RC48-ADC alone or in combination with PD-1 inhibitors for patients with locally advanced or metastatic urothelial carcinoma: A multicenter, retrospective clinical study.
    Xu J; Zhang H; Zhang L; Chu X; Li Y; Li G; Nie C; Wang M; Guo Y
    Cancer Med; 2023 Dec; 12(23):21159-21171. PubMed ID: 37935113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world sequential treatment patterns and clinical outcomes among patients with advanced urothelial carcinoma in Japan.
    Kita Y; Otsuka H; Ito K; Hara T; Shimura S; Kawahara T; Kato M; Kanamaru S; Inoue K; Ito H; Igarashi A; Sazuka T; Takamatsu D; Hashimoto K; Abe T; Naito S; Matsui Y; Nishiyama H; Kitamura H; Kobayashi T;
    Int J Urol; 2024 May; 31(5):552-559. PubMed ID: 38303567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.